Urogen Pharma (URGN) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady [Yahoo! Finance]
Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI